Proactive Investors - Run By Investors For Investors

Sphere Medical: CE mark paves the way for full commercial launch of blood monitor

Sphere Medical has received the final approval that paves the way for the commercial launch of its breakthrough blood monitor later this year.


Shares in Sphere Medical (LON:SPHR) spiked 5% after it said it had received the final approval that paves the way for the commercial launch of its breakthrough blood monitor later this year.  

The group has attained its CE mark under the EU Medical Devices Directive, which means its Proxima system complies with European product legislation. In all it has four CE marks.

The company in a statement said it will go ahead with what it called a post market clinical follow-up study, which will be carried out at the Queen Elizabeth Hospital in Birmingham, as well as heading into the full commercial launch of Proxima.

Sphere will initially target “key strategic UK hospitals in specific clinical application areas suitable for early adoption of the Proxima system”, investors were told.

The CE mark news was given alongside a broader update on the company in which it was revealed Sphere’s losses in the first quarter were smaller than anticipated. It has £7.8mln on the balance sheet.  

Since the appointment of Wolfgang Rencken as chief executive in February, the company said the focus has been on “bringing about a commercial and customer-centred culture at Sphere Medical”. 

Rencken added: "Within the past three months, since my appointment as CEO, I have been impressed by the potential of the Proxima technology.  

“A very considerable effort has gone into the CE marking process and today's announcement of its successful completion represents a significant milestone for the company and is the beginning of Proxima's commercial future.  

“This is an exciting time for the company, its partners, investors and staff and I am delighted to have joined at such a pivotal time."

A 3.20pm the shares were up 1.44p at 28.44p. 

View full SPHR profile View Profile

Sphere Medical Holding PLC Timeline

Related Articles

scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
December 03 2018
The readout of clinical trials is expected this month.
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use